N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up
Authors:
- Vladimir DzavikVDVladimir Dzavik
- Phong Nguyen-HoPNPhong Nguyen-Ho
- Robert RichardsonRRRobert Richardson
- Jan MitchellJMJan Mitchell
- Deborah AtchisonDADeborah Atchison
- Peter SeidelinPSPeter Seidelin
- Paul DalyPDPaul Daly
- John RossJRJohn Ross
- Peter R. McLaughlinPMPeter R. McLaughlin
- Douglas IngDIDouglas Ing
- Peter LewyckyPLPeter Lewycky
- 1 October 2004
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 148 (4) , 690-695
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID studyJACC, 2003
- Prevention of Contrast NephropathyJAMA, 2003
- Acetylcysteine for Prevention of Acute Deterioration of Renal Function Following Elective Coronary Angiography and InterventionJAMA, 2003
- A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiographyKidney International, 2002
- Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedureJACC, 2002
- Acetylcysteine and contrast agent-associated nephrotoxicityJACC, 2002
- Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial)The American Journal of Cardiology, 2002
- The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiencyJACC, 2000
- Acetylcysteine and Nephrotoxic Effects of Radiographic Contrast Agents — A New Use for an Old DrugNew England Journal of Medicine, 2000
- Prevention of Radiographic-Contrast-Agent–Induced Reductions in Renal Function by AcetylcysteineNew England Journal of Medicine, 2000